Piombino Dese, Italy — Stevanato Group S.p.A. said it has introduced Deora, a proprietary pen injector platform designed for subcutaneous drug delivery in therapies such as diabetes and weight management.
The company said the multi-use, fixed-dose pen injector targets incretin-based therapies and can also support other originator and biosimilar drug development programs.
Deora uses a pull-push mechanism for dose setting and delivery. Users pull to set the dose and push to inject, eliminating the need for manual dose selection. Stevanato Group said the design is intended to reduce common sources of use error and support consistent delivery across multiple administrations.
The platform is compatible with standard 1.5 mL and 3 mL cartridges and can accommodate fixed-dose volumes up to 0.75 mL.
“With Deora™, we are broadening our product offering in therapeutic areas experiencing strong global demand and favorable market momentum,” said Michele Monico, President of Drug Delivery Systems and In Vitro Diagnostics at Stevanato Group. “We believe there is space for a simple, multi-use device that enhances the patient experience while simultaneously reducing the pressure on supply chain scale-up. Our belief has been supported by early customer interest, and we are providing our pharmaceutical partners with evaluation units to support early-stage testing and development activities.”
Stevanato Group said the device architecture allows flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. The company said Deora is also designed to integrate into existing supply chains, supporting industrialization and scalable manufacturing.
“Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format,” added Michele Monico. “Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs.”
Stevanato Group said Deora leverages its established manufacturing capabilities, with production aligned to support future commercialization. The company said its expertise in glass manufacturing, analytical services and device engineering allows it to offer integrated solutions for pharmaceutical partners.
